Latest Product Development News

Cycliq Group Limited reported a robust net operating cash flow of $964,000 for the December 2024 quarter, bolstered by government grants and disciplined cost management. The company ended the period with a healthy cash balance of $1.12 million, signaling improved liquidity.

Cape Range Ltd reports a robust 23% revenue increase in its Biztrak software business for the December 2024 quarter, alongside a 68% surge in cash receipts, while investing in strategic corporate initiatives to fuel future growth.

IXUP Limited reports strong sales momentum driven by its largest-ever contract with iGaming Ontario, alongside strategic cost reductions and a clear path to positive cash flow by late 2025.

InteliCare advances its AI-driven platform deployment across multiple Hardi Aged Care sites, while expanding its commercial pipeline and enhancing product capabilities.

RLG Ltd has successfully raised $900,000 through a two-tranche placement to fund the development of its food and health products and expand global sales channels. The second tranche, involving options issuance, awaits shareholder approval.

Suvo Strategic Minerals delivered a robust December quarter with soaring profits and an extended supply deal, while advancing innovative low carbon cement projects in Australia and Indonesia.

NEXION Group reported a robust 30% increase in cash receipts for Q2 FY25, driven by strong sales growth and new satellite sector contracts. The company is actively expanding its footprint in Southeast Asia while funding ongoing M&A activities through convertible notes.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Credit Corp Group has reported a robust 32% rise in underlying NPAT for H1 FY2025, driven by strong US collections and consumer lending growth, while reaffirming its full-year guidance and announcing a healthy interim dividend.

Credit Corp Group Limited has reported a remarkable turnaround for the half-year ended 31 December 2024, posting a 464% increase in profit after tax to $44.1 million and a 45% rise in revenue to $271.5 million. The company also declared a fully franked interim dividend of 32 cents per share, signalling confidence in ongoing growth.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.